News & Updates
Filter by Specialty:
Full-spectrum microbiome drug for IBS with constipation clears phase II trial
The next-generation oral full-spectrum microbiome drug EBX-102-02 appears to have an acceptable safety profile in patients with irritable bowel syndrome with constipation (IBS-C) while yielding improvements in symptom severity, abdominal pain, and stool consistency, according to the results of the phase IIa TrIuMPH* study.
Full-spectrum microbiome drug for IBS with constipation clears phase II trial
25 May 2025
Linerixibat quells cholestatic itch in PBC, enabling better sleep
The ileal bile acid transporter inhibitor linerixibat provides rapid and substantial relief from cholestatic pruritus, in turn reducing associated sleep disturbances, in patients with primary biliary cholangitis (PBC), as shown in the global, phase III GLISTEN trial.
Linerixibat quells cholestatic itch in PBC, enabling better sleep
23 May 2025
Seladelpar benefit in PBC sustained at 3 years
The selective PPARδ* agonist seladelpar continues to demonstrate benefit in patients with primary biliary cholangitis (PBC) in the long-term pooled analysis from the ongoing open-label phase III ASSURE trial.